Company intelligence / Profile preview

Artepharm

Fengshun (Industrial Park of Fengshun Economic Development Zone), Guangdong, China

Ownership: Private
Employees: ~200
Development stage: Other

Overview

Artequick® (artemisinin + piperaquine) is a WHO-recommended artemisinin-based combination therapy (ACT) for uncomplicated and severe falciparum malaria, with rapid fever and parasite clearance (16-30 hours and 36-60 hours, respectively) and low side effects; marketed in multiple countries including Nigeria, Tanzania, and Kenya

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

Artequick

Unknown

Partnerships

Guangzhou University of Chinese Medicine

Beyond the preview

Go deeper on Artepharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Artepharm.

Explore the full profile